|Bid||17.92 x 800|
|Ask||17.95 x 1000|
|Day's range||17.49 - 17.95|
|52-week range||15.68 - 57.46|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||24.83|
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax's (DVAX) topline comprising sales of hepatitis B vaccine Heplisav-B, vaccine adjuvant CpG 1018 and other revenues is expected to retain the growth momentum in Q3 results.
SAN DIEGO, October 27, 2021--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 8, 2021, at 4:30 p.m. Eastern Time to discuss financial results and operations.